Basilea Pharmaceutica AG
BPMUF
$71.00
-$0.60-0.84%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.74% | 49.64% | 9,803.52% | 1,488.24% | 725.50% |
| Total Depreciation and Amortization | 13.20% | 13.47% | 15.13% | 12.95% | 13.06% |
| Total Amortization of Deferred Charges | 2.43% | -40.61% | -58.20% | -63.07% | -65.15% |
| Total Other Non-Cash Items | 167.41% | 154.65% | 135.28% | -74.51% | -536.61% |
| Change in Net Operating Assets | 55.61% | -57.18% | -103.29% | -49.77% | 260.22% |
| Cash from Operations | -10.95% | 71.88% | 693.39% | 534.32% | 452.87% |
| Capital Expenditure | -66.48% | -65.04% | -65.13% | -85.16% | -114.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -100.00% | -3.31% | -- |
| Other Investing Activities | -217.01% | -37.09% | 37.07% | 51.79% | 62.43% |
| Cash from Investing | -203.92% | -239.43% | -345.42% | -94.06% | -0.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 86.53% | 73.69% |
| Issuance of Common Stock | -71.87% | -76.87% | -80.54% | -46.69% | -0.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -105,219.05% | -14,399.22% | -6,317.80% | -2,042.23% | 95.55% |
| Cash from Financing | -72.34% | 43.53% | 72.05% | 75.46% | 76.94% |
| Foreign Exchange rate Adjustments | -157.56% | -658.00% | -132.66% | 86.71% | 132.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.56% | 483.21% | 247.77% | 242.32% | 237.51% |